Clinical Trial Update: Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating topical ruxolitinib cream for refractory cutaneous dermatomyositis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Dermatomyositis
• Dermatomyositis

Drugs mentioned

• Opzelura (ruxolitinib)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Dermatomyositis | Phase 2 | Status: RECRUITING